#75
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians need to recognize cannabinoid hyperemesis syndrome (CHS) as a potential diagnosis in patients presenting with severe, intractable vomiting, particularly those who vape cannabis regularly, since vaping may deliver higher cannabinoid concentrations than other consumption methods. Understanding this dose-response relationship helps providers counsel patients about consumption risks and distinguish CHS from other causes of cyclic vomiting that would require different treatment approaches. Early identification of CHS allows for appropriate management including cannabinoid cessation, which is the only definitive treatment, rather than unnecessary diagnostic workups or ineffective antiemetic medications.
A California study published in Cannabis and Cannabinoid Research identified an association between cannabis vaping and cannabinoid hyperemesis syndrome (CHS), a condition characterized by severe, intractable vomiting in otherwise healthy individuals. The research adds to growing evidence that the consumption method and potency of cannabis products may influence the risk of developing this serious adverse effect, particularly as vaping delivers high concentrations of cannabinoids rapidly to the systemic circulation. CHS presents a diagnostic challenge for clinicians because patients often undergo extensive gastrointestinal workups before cannabis use is identified as the culprit, delaying appropriate management and causing unnecessary suffering. This finding is particularly relevant given the proliferation of high-potency vaping products in legal cannabis markets, which may concentrate cannabinoids at levels substantially higher than traditional smoking methods. Clinicians should maintain heightened suspicion for CHS in patients presenting with severe, refractory nausea and vomiting, particularly those using cannabis vape products, and counsel patients that switching to lower-potency consumption methods or cessation may resolve symptoms. For patients using cannabis therapeutically, discussing the relative risks of different delivery methods can help inform shared decision-making around product selection and consumption patterns.
“Cannabinoid hyperemesis syndrome is real and underdiagnosed, particularly in patients who’ve transitioned to vaping, and we need to screen for it systematically because the condition is entirely reversible with cessation. What concerns me clinically is that many patients suffer for months or years before anyone connects their symptoms to cannabis use, so I now take a detailed consumption history including frequency, dose, and delivery method in anyone presenting with cyclic vomiting.”
? Recent California research associating cannabis vaping with cannabinoid hyperemesis syndrome (CHS) adds to a growing body of evidence that inhalation delivery may carry distinct risks compared to other cannabis administration routes. While CHS has been documented in medical literature for over a decade, the specific link to vaping warrants clinical attention given the popularity of this consumption method, particularly among younger users who may underestimate their exposure risk. Clinicians should recognize that the syndrome’s presentation can mimic gastroenteritis or primary GI disorders, potentially leading to unnecessary investigations and delayed diagnosis in patients with recurrent nausea and vomiting. Important caveats include the challenge of establishing causality in observational studies, variable cannabinoid concentrations across vaping products, and the possibility that vaping’s rapid absorption and high THC delivery may trigger CHS in susceptible individuals rather than being unique to the route itself. When evaluating patients with cyc
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
